Changes of ADAM metallopeptidase domain 23 expression in hepatic fibrosis of mice infected with Echinococcus multilocularis

doi:10.12140/j.issn.1000-7423.2025.06.005

Abstract

Abstract:

Objective To investigate the changes of ADAM metallopeptidase domain 23 (ADAM23) expression during the progression of hepatic fibrosis in mice infected with Echinococcus multilocularis (Em). Methdos Thirty-six C57BL/6 mice were randomly divided into six groups, of 6 mice each group, including the 1-month sham group, 1-month Em infection group, 3-month sham group, 3-month Em infection group, 6-month sham group, and 6-month Em infection group. Mice in the Em infection groups were injected with Em protoscolex suspensions (2 000 protoscoleces/mouse) via the portal vein, while animals in the sham groups received an equal volume of physiological saline. Mouse liver tissues were sampled 1, 3 and 6 months post-infection. Hepatic lobule structure, inflammatory cell infiltration, granuloma formation, and collagen deposition were observed by HE and Sirius red staining, and target protein expression was quantified using immunohistochemical staining. Mouse liver tissues from the 3-month sham and 3-month Em infection groups were sampled for proteomic analyses, and the translational and transcriptional expression of ADAM23, α-smooth muscle actin (α-SMA), and collagen type 1 alpha 1 chain (COL1A1) was determined in mice using Western blotting and RT-qPCR assays. Human hepatic stellate cells (HSCs) were seeded onto 6-well plates at a density of 2 × 10⁵ cells/well and divided into the si-ADAM23 group, TGF-β1 + small interfering RNA (siRNA) group, TGF-β1 + si-ADAM23 group, siRNA group, and control group. Cells were transfected with 600 ng siRNA-ADAM23 in the si-ADAM23 group, received 10 ng TGF-β1 and 600 ng siRNA cells in the TGF-β1 + siRNA group, received 10 ng TGF-β1 and 600 ng siRNA-ADAM23 in the TGF-β1 + si-ADAM23 group, received 600 ng siRNA in the siRNA group, and received an equal volume of transfection reagents in the control group. The translational and transcriptional expression of ADAM23, α-SMA, and COL1A1 was detected in HSCs using Western blotting and RT-qPCR assays. Results HE staining showed hepatic lobule structural derangements with infiltration of a large number of inflammatory cells in Em-infected mice. Sirius red staining revealed that the areas of hepatic fibrosis were (2 167.00 ± 356.70) μm², (163.10 ± 25.41) μm², (3 792.00 ± 596.00) μm², (159.40 ± 3.97) μm², (5 436.00 ± 427.50) μm², (274.40 ± 38.01) μm² in the 1, 3, and 6-month Em infection groups and corresponding sham groups, respectively, with significant differences seen between the infection and sham groups (t = 14.71, 26.68 and 37.91; all P < 0.05). Proteomic analysis showed that the ADAM23 protein abundance was 9 250 ± 5 628 of in the 3-month Em infection group. Western blotting assay showed significant differences in ADAM23, α-SMA, and COL1A1 protein expression between the 1-, 3-, 6-month Em infection groups and their corresponding sham groups (t = 13.5, 15.8, 26.1; 4.37, 6.75, 15.82; 5.00, 8.65 and 21.45; all P < 0.05). RT-qPCR assay quantified significant differences in the relative mRNA expression of adam23, acta2, and col1a1 between the 1-, 3-, 6-month Em infection groups and their corresponding sham groups (t = 5.44, 6.44, 9.95; 4.13, 7.43, 25.10; 4.85, 22.60 and 39.50; all P values < 0.05). Immunohistochemistry showed significant differences in the area of positive ADAM23, α-SMA, and COL1A1 expression the 1-, 3-, 6-month Em infection groups and their corresponding sham groups (t = 26.68, 17.55, 52.07; 24.98, 36.70, 49.47; 16.24, 45.48 and 77.45; all P < 0.05). Spearman correlation analysis revealed that the area of positive ADAM23 expression positively correlated with the areas of positive α-SMA (r = 0.83, P < 0.05) and COL1A1 expression (r = 0.87, P < 0.05), and Sirius red staining (r = 0.88, P < 0.05) in liver samples of Em-infected mice. RT-qPCR assay quantified that the relative adam23 mRNA expression was 1.03 ± 0.14, 0.92 ± 0.09, and 0.23 ± 0.04 in HSCs in the control, siRNA, and si-ADAM23 groups, respectively, and higher relative adam23 mRNA expression was found in the siRNA group than in the si-ADAM23 group (t = 12.23, P < 0.05). Western blotting assay showed that the relative ADAM23 protein expression was 0.15 ± 0.01, 1.20 ± 0.11, and 0.41 ± 0.15 in the siRNA group, TGF-β1 + siRNA group, and TGF-β1 + si-ADAM23 group, statistically significant differences were observed both when comparing the siRNA group with the TGF-β1 + siRNA group, and when comparing the TGF-β1 + siRNA group with the TGF-β1 + si-ADAM23 group (t = 16.52 and 12.44, both P < 0.05), and the relative α-SMA protein expression was 0.31 ± 0.09, 1.21 ± 0.04, and 0.87 ± 0.01 in the siRNA group, TGF-β1 + siRNA group, and TGF-β1 + si-ADAM23, statistically significant differences were observed both when comparing the siRNA group with the TGF-β1 + siRNA group, and when comparing the TGF-β1 + siRNA group with the TGF-β1 + si-ADAM23 group (t = 27.85 and 10.67, both P values < 0.05), while the relative COL1A1 protein expression was 0.61 ± 0.16, 0.95 ± 0.02, and 0.49 ± 0.07 in the siRNA group, TGF-β1 + siRNA group, and TGF-β1 + si-ADAM23 group, statistically significant differences were observed both when comparing the siRNA group with the TGF-β1 + siRNA group, and when comparing the TGF-β1 + siRNA group with the TGF-β1 + si-ADAM23 group (t = 5.77 and 7.96, both P values < 0.05). Conclusion ADAM23 expression increases with the progression of Em infections and positively correlates with the degree of hepatic fibrosis. ADAM23 is a novel potential therapeutic target for hepatic fibrosis caused by Em infections.

Key words: Echinococcus multilocularis, Hepatic fibrosis, Hepatic stellate cells, ADAM23

CLC Number:

R532.32

ZHANG Hongbin, SHI Bowen, ZHENG Xue, LI Xiaotong, XUE Junlong, YANG Ning, BI Xiaojuan, LIN Renyong. Changes of ADAM metallopeptidase domain 23 expression in hepatic fibrosis of mice infected with Echinococcus multilocularis[J]. CHINESE JOURNAL OF PARASITOLOGY AND PARASITIC DISEASES, 2025, 43(6): 777-785.

Figures/Tables 6

Table 1

Fig. 1

Fig. 2

Fig. 3

Fig. 4

Fig. 5

References 30

[1]	Wang X, Xiao ZJ, Xue CZ, et al. Clinical confirmation of an infection with Echinococcus multilocularis (Mongolian genotype): First case report of human alveolar echinococcosis in Inner Mongolia, China[J]. Infect Dis Poverty, 2025, 14: 74.
[2]	Fu MH, Wang X, Han S, et al. Advances in research on echinococcoses epidemiology in China[J]. Acta Trop, 2021, 219: 105921.
[3]	Lundstr?m-Stadelmann B, Rostami A, Frey CF, et al. Human alveolar echinococcosis-global, regional, and national annual incidence and prevalence rates[J]. Clin Microbiol Infect, 2025, 31(7): 1139-1145.
[4]	Zhang CS, Wang H, Li J, et al. Involvement of TIGIT in natural killer cell exhaustion and immune escape in patients and mouse model with liver Echinococcus multilocularis infection[J]. Hepatology, 2021, 74(6): 3376-3393.
[5]	Lv T, Xu G, Xu X, et al. A novel remnant liver-first strategy for liver autotransplantation in patients with end-stage hepatic alveolar echinococcosis: A retrospective case series[J]. Int J Surg, 2023, 109(11): 3262-3272.
[6]	Zhu DL, Tulahong A, Liu C, et al. Identification of key factors and explainability analysis for surgical decision-making in hepatic alveolar echinococcosis assisted by machine learning[J]. World J Gastroenterol, 2025, 31(37): 111038.
[7]	Roehlen N, Crouchet E, Baumert TF. Liver fibrosis: Mechanistic concepts and therapeutic perspectives[J]. Cells, 2020, 9(4): 875.
[8]	Sharma D, Singh NK. The biochemistry and physiology of a disintegrin and metalloproteinases (ADAMs and ADAM-TSs) in human pathologies[J]. Rev Physiol Biochem Pharmacol, 2023, 184: 69-120.
[9]	Xu JM, Wang Y, Jiang JH, et al. ADAM12 promotes clear cell renal cell carcinoma progression and triggers EMT via EGFR/ERK signaling pathway[J]. J Transl Med, 2023, 21(1): 56.
[10]	Kawai T, Elliott KJ, Scalia R, et al. Contribution of ADAM17 and related ADAMs in cardiovascular diseases[J]. Cell Mol Life Sci, 2021, 78(9): 4161-4187.
[11]	Huovila AJ, Turner AJ, Pelto-Huikko M, et al. Shedding light on ADAM metalloproteinases[J]. Trends Biochem Sci, 2005, 30(7): 413-422.
[12]	Meng QM, Bao D, Liu SJ, et al. ADAM metallopeptidase doma in 19 promotes skin fibrosis in systemic sclerosis via neuregulin-1[J]. Mol Med, 2024, 30(1): 269.
[13]	Li Y, Xue J, Zhang WQ, et al. ADAM15 in fibroblasts: Improving the matrix remodeling by blocking the action of transforming growth factor-β1[J]. Ann Clin Lab Sci, 2024, 54(3): 363-370.
[14]	Hirano Y, Miyazaki Y, Ishikawa D, et al. Biallelic LGI1 and ADAM23 variants cause hippocampal epileptic encephalopathy via the LGI1-ADAM22/23 pathway[J]. Brain, 2025, 148(10): 3514-3522.
[15]	刘萍, 李云峰, 李强, 等. EGFR、αVβ3、ADAM23在大肠癌中的表达及临床意义[J]. 实用癌症杂志, 2016, 31(1): 1-3.
	Liu P, Li YF, Li Q, et al. Expression and clinical significance of EGFR, αVβ3 and ADAM23 in colorectal cancer[J]. Pract J Cancer, 2016, 31(1): 1-3. (in Chinese)
[16]	Kern P, Menezes da Silva A, Akhan O, et al. The echinococcoses: Diagnosis, clinical management and burden of disease[J]. Adv Parasitol, 2017, 96: 259-369.
[17]	Salzmann M, Resch U, Boccuni L, et al. Phytic acid impairs macrophage inflammatory response in Echinococcus multilocularis infection[J]. Commun Biol, 2025, 8(1): 871.
[18]	Liu TL, Pu GT, Wang LQ, et al. LncRNA gm40262 promotes liver fibrosis and parasite growth through the gm40262-miR-193b-5p-TLR4/Col1α1 axis[J]. mBio, 2025, 16(4): e02287-24.
[19]	Lachowski D, Matellan C, Gopal S, et al. Substrate stiffness-driven membrane tension modulates vesicular trafficking via caveolin-1[J]. ACS Nano, 2022, 16(3): 4322-4337.
[20]	Kisseleva T, Brenner D. Molecular and cellular mechanisms of liver fibrosis and its regression[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(3): 151-166.
[21]	武士豪, 何钰宏, 李嘉兴, 等. 肝星状细胞的代谢重编程在肝纤维化发展中的研究现状[J]. 广东医科大学学报, 2024(5): 518-522, 534.
	Wu SH, He YH, Li JX, et al. Overview of the role of metabolic reprogramming of hepatic stellate cells in liver fibrosis[J]. J Guangdong Med Univ, 2024(5): 518-522, 534. (in Chinese)
[22]	Kim JW, Kim YJ. The evidence-based multifaceted roles of hepatic stellate cells in liver diseases: A concise review[J]. Life Sci, 2024, 344: 122547.
[23]	Cao SL, Wang DX, Wu YX, et al. Mmu-miRNA-342-3p promotes hepatic stellate cell activation and hepatic fibrosis induced by Echinococcus multilocularis infection via targeting Zbtb7a[J]. PLoS Negl Trop Dis, 2023, 17(7): e0011520.
[24]	Edwards DR, Handsley MM, Pennington CJ. The ADAM metalloproteinases[J]. Mol Aspects Med, 2008, 29(5): 258-289.
[25]	Yan SY, Zhao YQ, Xu W, et al. ADAM17/PTGS2 facilitates pulmonary fibrosis by regulating ferroptosis[J]. J Cell Mol Med, 2025, 29(5): e70466.
[26]	Saad MI, McLeod L, Hodges C, et al. ADAM17 deficiency protects against pulmonary emphysema[J]. Am J Respir Cell Mol Biol, 2021, 64(2): 183-195.
[27]	杨孟利, 李三强, 张凯杰, 等. 抑制解整合素金属蛋白酶8表达对酒精性肝纤维化小鼠炎症损伤的机制[J]. 解剖学报, 2024, 55(6): 746-752.
	Yang ML, Li SQ, Zhang KJ, et al. Mechanism of inhibiting the expression of disintegrin metalloproteinase-8 on inflammatory injury in mice with alcoholic liver fibrosis[J]. Acta Anat Sin, 2024, 55(6): 746-752. (in Chinese)
[28]	Peng ZH, Konai MM, Avila-Cobian LF, et al. MMP-1 and ADAM10 as targets for therapeutic intervention in idiopathic pulmonary fibrosis[J]. ACS Pharmacol Transl Sci, 2022, 5(8): 548-554.
[29]	林婧怡, 韩壤乐, 徐玲慧, 等. 黄芪三七合剂抑制lncRNA Gm51500/Adam12轴改善CKD肾脏纤维化[J]. 中国临床药理学与治疗学, 2025, 30(6): 750-762.
	Lin JY, Han RL, Xu LH, et al. Huangqi Sanqi mixture inhibits lncRNA Gm51500/Adam12 axis and improves renal fibrosis in CKD[J]. Chin J Clin Pharmacol Ther, 2025, 30(6): 750-762. (in Chinese)
[30]	孔深柯, 张学军, 马培尧, 等. miR-126通过ADAM9调控自发性高血压大鼠的心肌纤维化[J]. 武汉大学学报(医学版), 2024, 45(1): 25-30.
	Kong SK, Zhang XJ, Ma PY, et al. MiR-126 regulates myocardial fibrosis in spontaneously hypertensive rats through ADAM9[J]. Med J Wuhan Univ, 2024, 45(1): 25-30. (in Chinese)

基因 Gene	正向引物（5′→3′）Forward primer (5′→3′)	反向引物（5′→3′）Reverse primer (5′→3′)
adam23	CCACCGAACCTCCATAA	TCCTTGAAGTTGACCGATA
acta2	GTCCCAGACATCAGGGAGTAA	TCGGATACTTCAGCGTCAGGA
col1a1	GCTCCTCTTAGGGGCCACT	ATTGGGGACCCTTAGGCCAT
GAPDH	AGGTCGGTGTGAACGGATTTG	TGTAGACCATGTAGTTGAGGTCA
adam23	GATACGGATGTGGGCTAT	TGCTCATATTTAGGGCTTG
acta2	GTGTTGCCCCTGAAGAGCAT	GCTGGGACATTGAAAGTCTCA
col1a1	CCCGGGTTTCAGAGACAACTTC	TCCACATGCTTTATTCCAGCAATC
GAPDH	GCACCGTCAAGGCTGAGAAC	TGGTGAAGACGCCAGTGGA